Your browser doesn't support javascript.
loading
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol, Laura; Hebraud, Benjamin; Oriol, Albert; Colin, Anne-Laurène; Ríos Tamayo, Rafael; Hulin, Cyrille; Blanchard, María Jesús; Caillot, Denis; Sureda, Anna; Hernández, Miguel Teodoro; Arnulf, Bertrand; Mateos, Maria-Victoria; Macro, Margaret; San-Miguel, Jesús; Belhadj, Karim; Lahuerta, Juan José; Garelik, M Brigid; Bladé, Joan; Moreau, Philippe.
Afiliação
  • Rosiñol L; Department of Hematology, Hospital Clínic Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Hebraud B; Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Oriol A; Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Colin AL; Service de Pharmacologie Médicale et Clinique, Centre Hospitalier et Universitaire de Toulouse, Toulouse, France.
  • Ríos Tamayo R; Department of Hematology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
  • Hulin C; Department of Hematology, Hôpital Haut-Lévêque, Bordeaux Pessac, France.
  • Blanchard MJ; Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.
  • Caillot D; CHU Dijon, Hôpital du Bocage, Dijon, France.
  • Sureda A; Institut Català d'Oncologia-Hospitalet i Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
  • Hernández MT; Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • Arnulf B; Centre Hospitalier Universitaire, Hôpital St-Louis, Paris, France.
  • Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
  • Macro M; Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen, France.
  • San-Miguel J; Clínica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.
  • Belhadj K; Lymphoid Malignancies Unit, Centre Hospitalier et Universitaire Henri Mondor, Creteil, France.
  • Lahuerta JJ; Clínica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain.
  • Garelik MB; Celgene, Bristol-Myers Squibb Company, Summit, NJ, United States.
  • Bladé J; Department of Hematology, Hospital Clínic Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Front Oncol ; 13: 1197340, 2023.
Article em En | MEDLINE | ID: mdl-38023148
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article